An exploratory analysis of the cost‐effectiveness of insulin glargine 300 units/mL versus insulin glargine 100 units/mL over a lifetime horizon using the BRAVO diabetes model
Authors' conclusion
Gla-300 may be a cost-effective treatment option versus Gla-100 over a lifetime horizon for insulin-naïve people in the United States with T2D inadequately controlled on OADs.
Study context
- Population
- Insulin-naïve adults with T2D inadequately controlled with oral antidiabetic drugs (OADs); baseline data from EDITION-3 RCT
- Comparison
- Gla-300 vs Gla-100
- Outcome
- ICER (lifetime costs and QALYs)
- Follow-up
- Lifetime horizon
Methodological detailsBRAVO diabetes model, exploratory, lifetime horizon, US healthcare payer perspective, scenario and sensitivity analyses
- BRAVO diabetes model
- Exploratory
- Lifetime horizon
- US healthcare payer perspective
- Scenario and sensitivity analyses
Main finding
As reported in the abstract
Lifetime medical costs, QALYs and ICER
Incremental cost-effectiveness ratio (ICER)
$7522 /QALY gained
cost-effective at WTP threshold of $50,000/QALY
Net monetary benefit
$3290
Lifetime medical costs, quality-adjusted life-years (QALYs) and ICER
Gla-300
$353,441
Gla-100
$352,858
Further findings
- Scenario and sensitivity analyses confirmed the robustness of the base case
Original publication
An exploratory analysis of the cost‐effectiveness of insulin glargine 300 units/mL versus insulin glargine 100 units/mL over a lifetime horizon using the BRAVO diabetes model. Diabet Med. Published 12 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →